Pervasive glycative stress links metabolic imbalance and muscle atrophy in early-onset Parkinson's disease.

普遍存在的糖化应激与早发性帕金森病中的代谢失衡和肌肉萎缩有关

阅读:5
作者:de Mello Natalia Prudente, Berger Michelle Tamara, Lagerborg Kim A, Yan Yingfei, Wettmarshausen Jennifer, Keipert Susanne, Weidner Leopold, Tokarz Janina, Möller Gabriele, Ciciliot Stefano, Walia Safal, Cheng Yiming, Chudenkova Margarita, Artati Anna, Weisenhorn Daniela Vogt, Wurst Wolfgang, Adamski Jerzy, Nilsson Roland, Cossu Giovanni, Boon Agnita, Kievit Anneke, Mandemakers Wim, Bonifati Vincenzo, Jain Mohit, Jastroch Martin, Schmitt-Kopplin Philippe, Perocchi Fabiana, Dyar Kenneth Allen
OBJECTIVE: Parkinson's disease (PD) is recognized as a systemic condition, with clinical features potentially modifiable by dietary intervention. Diets high in saturated fats and refined sugars significantly increase PD risk and exacerbate motor and non-motor symptoms, yet precise metabolic mechanisms are unclear. Our objective here was to investigate the interplay between diet and PD-associated phenotypes from a metabolic perspective. METHODS: We explored PARK7 KO mice under chronic glycative stress induced by prolonged high-fat high-sucrose (HFHS) diet. We investigated metabolic consequences by combining classical metabolic phenotyping (body composition, glucose tolerance, indirect calorimetry, functional assays of isolated mitochondria) with metabolomics profiling of biospecimens from mice and PD patients. RESULTS: We found this obesogenic diet drives loss of fat and muscle mass in early-onset PD mice, with a selective vulnerability of glycolytic myofibers. We show that PD mice and early-onset familial PD patients are under pervasive glycative stress with pathological accumulation of advanced glycation end products (AGEs), including N-α-glycerinylarginine (α-GR) and N-α-glycerinyllysine (α-GK), two previously unknown glycerinyl-AGE markers. CONCLUSIONS: Our results offer the first proof for a direct link between diet, accumulation of AGEs and genetics of PD. We also expand the repertoire of clinically-relevant glycative stress biomarkers to potentially define at-risk patients before neurological or metabolic symptoms arise, and/or to monitor disease onset, progression, and effects of interventions.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。